Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Mangoceuticals (MGRX) EBT Margin (2023 - 2025)

Mangoceuticals (MGRX) has disclosed EBT Margin for 3 consecutive years, with 2934.9% as the latest value for Q4 2025.

  • Quarterly EBT Margin fell 108345.0% to 2934.9% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 4526.86% through Dec 2025, down 311306.0% year-over-year, with the annual reading at 4526.86% for FY2025, 311306.0% down from the prior year.
  • EBT Margin hit 2934.9% in Q4 2025 for Mangoceuticals, up from 9043.49% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 733.99% in Q3 2023 to a low of 9043.49% in Q3 2025.
  • Historically, EBT Margin has averaged 2624.53% across 3 years, with a median of 1734.3% in 2023.
  • Biggest five-year swings in EBT Margin: surged 143666bps in 2024 and later plummeted -754411bps in 2025.
  • Year by year, EBT Margin stood at 1050.87% in 2023, then crashed by -76bps to 1851.45% in 2024, then crashed by -59bps to 2934.9% in 2025.
  • Business Quant data shows EBT Margin for MGRX at 2934.9% in Q4 2025, 9043.49% in Q3 2025, and 3221.61% in Q2 2025.